Is quantitative benefit–risk modelling of drugs desirable or possible?

Phillips, Lawrence D., Fasolo, Barbara ORCID: 0000-0002-4643-5689, Zafiropoulos, Nikolaos and Beyer, Andrea (2011) Is quantitative benefit–risk modelling of drugs desirable or possible? Drug Discovery Today: Technologies, 8 (1). e3-e10. ISSN 1740-6749

Full text not available from this repository.

• Author
• Author

Abstract

Preliminary research results with drug regulators in several European Agencies show that quantitative models developed with groups of assessors and specialists can integrate scientific data with expert value judgements, thereby extending the capabilities of regulators, and stimulating new insights about key trade-offs. As a result, the rationale for the benefit-risk balance becomes more transparent, communicable and consistent.

Item Type:	Article
Official URL:	http://www.journals.elsevier.com/drug-discovery-to...
Additional Information:	© 2011 Elsevier
Divisions:	Management
Subjects:	R Medicine > RS Pharmacy and materia medica
Date Deposited:	24 Nov 2011 09:53
Last Modified:	23 Apr 2024 04:33
URI:	http://eprints.lse.ac.uk/id/eprint/39733

Actions (login required)

View Item